Announcements Trials

Browse Landscape

Phase

Status

Recruiting 3 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 13 Melanoma 11 Triple Negative Breast Neoplasms 9 Squamous Cell Carcinoma of Head and Neck 8 Breast Neoplasms 8 Neoplasms 7 Head and Neck Neoplasms 7 Multiple Myeloma 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 6 Pancreatic Neoplasms 5 Lung Neoplasms 4 Recurrence 3 Prostatic Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Brain Neoplasms 3 Stomach Neoplasms 2 Sarcoma 2 Neoplasm Metastasis 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Kidney Neoplasms 2 Inflammatory Breast Neoplasms 2 Hematologic Neoplasms 2 Glioblastoma 2 Urothelial Cancer 1 Thyroid Neoplasms 1 Subcutaneous panniculitis-like T-cell lymphoma 1 Spinocerebellar Degenerations 1

Interventions

Gemcitabine 2 Docetaxel 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tanespimycin 1 selinexor 1 pembrolizumab 1 olaparib 1 ixazomib 1 Glutamine 1 Fulvestrant 1 Adjuvants, Pharmaceutic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Liposarcoma × pembrolizumab × Clear all

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡